Zolazepam
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Zolazepam
- DrugBank Accession Number
- DB11555
- Background
Zolazepam is a pyrazolodiazepinone derivative used as an anaesthetic in veterinary medicine. Zolazepam is typically used in combination with the NMDA antagonist tiletamine or the α2 adrenoceptor agonist xylazine. It is around four times the potency of diazepam but it is both water-soluble and un-ionized at physiological pH meaning that its onset is very fast.
- Type
- Small Molecule
- Groups
- Vet approved
- Structure
- Weight
- Average: 286.31
Monoisotopic: 286.122989282 - Chemical Formula
- C15H15FN4O
- Synonyms
- Zolazepam
- Zolazepamum
- External IDs
- CI 716
- CI-716
- DEA No. 7295
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when Zolazepam is combined with 1,2-Benzodiazepine. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Zolazepam. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Zolazepam. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Zolazepam. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Zolazepam. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Zolazepam hydrochloride 45SJ093Q1N 33754-49-3 NJERAXSSDSHLGE-UHFFFAOYSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acids and derivatives
- Alternative Parents
- Fluorobenzenes / Aryl fluorides / Tertiary carboxylic acid amides / Pyrazoles / Heteroaromatic compounds / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds show 4 more
- Substituents
- Alpha-amino acid or derivatives / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Azole / Benzenoid / Carbonyl group / Carboxamide group / Fluorobenzene show 20 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- G1R474U58U
- CAS number
- 31352-82-6
- InChI Key
- GDSCFOSHSOWNDL-UHFFFAOYSA-N
- InChI
- InChI=1S/C15H15FN4O/c1-9-13-14(10-6-4-5-7-11(10)16)17-8-12(21)19(2)15(13)20(3)18-9/h4-7H,8H2,1-3H3
- IUPAC Name
- 4-(2-fluorophenyl)-1,3,8-trimethyl-1H,6H,7H,8H-pyrazolo[3,4-e][1,4]diazepin-7-one
- SMILES
- CN1N=C(C)C2=C1N(C)C(=O)CN=C2C1=CC=CC=C1F
References
- General References
- Natalini CC, Alves SD, Guedes AG, Polydoro AS, Brondani JT, Bopp S: Epidural administration of tiletamine/zolazepam in horses. Vet Anaesth Analg. 2004 Apr;31(2):79-85. [Article]
- Hubbell JA, Bednarski RM, Muir WW: Xylazine and tiletamine-zolazepam anesthesia in horses. Am J Vet Res. 1989 May;50(5):737-42. [Article]
- Hong WH, Szulczewski DH: Characteristics of equilibrium reaction of zolazepam. J Pharm Sci. 1981 Jun;70(6):691-3. [Article]
- Wilson RP, Zagon IS, Larach DR, Lang CM: Cardiovascular and respiratory effects of tiletamine-zolazepam. Pharmacol Biochem Behav. 1993 Jan;44(1):1-8. [Article]
- Cattet MR, Caulkett NA, Lunn NJ: Anesthesia of polar bears using xylazine-zolazepam-tiletamine or zolazepam-tiletamine. J Wildl Dis. 2003 Jul;39(3):655-64. [Article]
- Lin HC, Wallace SS, Tyler JW, Robbins RL, Thurmon JC, Wolfe DF: Comparison of tiletamine-zolazepam-ketamine and tiletamine-zolazepam-ketamine-xylazine anaesthesia in sheep. Aust Vet J. 1994 Aug;71(8):239-42. [Article]
- Fernandez-Moran J, Palomeque J, Peinado VI: Medetomidine/tiletamine/zolazepam and xylazine/tiletamine/zolazepam combinations for immobilization of fallow deer (Cervus dama). J Zoo Wildl Med. 2000 Mar;31(1):62-4. [Article]
- Caulkett NA, Cattet MR, Cantwell S, Cool N, Olsen W: Anesthesia of wood bison with medetomidine-zolazepam/tiletamine and xylazine-zolazepam/tiletamine combinations. Can Vet J. 2000 Jan;41(1):49-53. [Article]
- Selmi AL, Mendes GM, Figueiredo JP, Guimaraes FB, Selmi GR, Bernal FE, McMannus C, Paludo GR: Chemical restraint of peccaries with tiletamine/zolazepam and xylazine or tiletamine/zolazepam and butorphanol. Vet Anaesth Analg. 2003 Jan;30(1):24-9. [Article]
- Cattet MR, Caulkett NA, Polischuk SC, Ramsay MA: Anesthesia of polar bears (Ursus maritimus) with zolazepam-tiletamine, medetomidine-ketamine, and medetomidine-zolazepam-tiletamine. J Zoo Wildl Med. 1999 Sep;30(3):354-60. [Article]
- External Links
- ChemSpider
- 32907
- 1535252
- ChEMBL
- CHEMBL2111144
- ZINC
- ZINC000000002259
- Wikipedia
- Zolazepam
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intramuscular; Intravenous - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.269 mg/mL ALOGPS logP 1.76 ALOGPS logP 1.26 Chemaxon logS -3 ALOGPS pKa (Strongest Basic) 2.38 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 50.49 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 87.97 m3·mol-1 Chemaxon Polarizability 28.9 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-05g0-1590000000-7482ab875abeada57f61 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0090000000-7e8c83355796347c11b5 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-000i-0090000000-f5be84dee32e5a8629a5 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0090000000-80de8210b41c830c6745 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-000i-0090000000-f65b1f41e9f3100efec3 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-00rg-0490000000-1a948bdaeba0d0e0dcd1 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0udi-0390000000-cf1607ec73b9dced8b19 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 157.07043 predictedDeepCCS 1.0 (2019) [M+H]+ 159.44121 predictedDeepCCS 1.0 (2019) [M+Na]+ 165.52158 predictedDeepCCS 1.0 (2019)
Drug created at February 26, 2016 17:46 / Updated at February 21, 2021 18:53